Natus Medical Inc  

(Public, NASDAQ:BABY)   Watch this stock  
Find more results for MAG Enterprises, LLC�
24.26
+0.51 (2.15%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.39 - 24.60
52 week 11.73 - 27.70
Open 23.60
Vol / Avg. 334,066.00/326,014.00
Mkt cap 774.00M
P/E 32.85
Div/yield     -
EPS 0.74
Shares 31.90M
Beta 1.11
Inst. own 83%
Jun 2, 2014
Natus Medical Incorporated Annual Shareholder Meeting (Estimated) Add to calendar
Apr 23, 2014
Q1 2014 Natus Medical Incorporated Earnings Conference Call - 11:00AM EDT - Add to calendar
Apr 23, 2014
Q1 2014 Natus Medical Incorporated Earnings Release - 9:30AM EDT - Add to calendar
Mar 10, 2014
Natus Medical Incorporated at ROTH Conference - Webcast
Mar 3, 2014
Natus Medical Inc at Raymond James Financial Inc Institutional Investors Conference - Webcast
Jan 29, 2014
Q4 2013 Natus Medical Incorporated Earnings Conference Call - Webcast
Jan 29, 2014
Q4 2013 Natus Medical Incorporated Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 10.07% 6.65%
Operating margin 15.58% 9.96%
EBITD margin - 15.50%
Return on average assets 8.70% 5.59%
Return on average equity 12.31% 7.96%
Employees 943 -
CDP Score - -

Address

1501 INDUSTRIAL ROAD
SAN CARLOS, CA 94070
United States - Map
+1-650-8020400 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Natus Medical Incorporated (Natus) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company�s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn�s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. Natus categorizes its products into three categories: Hearing, Neurology and Newborn Care. In July 2012, the Company acquired the Nicolet neurodiagnostic business from CareFusion.

Officers and directors

Robert A. Gunst Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James B. Hawkins President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jonathan A. Kennedy Chief Financial Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Steven J. Murphy Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Austin F. Noll III Vice President and General Manager - Neurology Strategic Business Unit
Bio & Compensation  - Reuters
Kenneth M. Traverso Vice President, General Manager - Newborn Care Strategic Business Unit
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
D. Christopher Chung M.D. Vice President - Medical Affairs, Quality & Regulatory
Age: 49
Bio & Compensation  - Reuters
Doris E. Engibous Independent Director
Age: 58
Bio & Compensation  - Reuters
Kenneth E. Ludlum Independent Director
Age: 60
Bio & Compensation  - Reuters
William M. Moore Jr. Independent Director
Age: 64
Bio & Compensation  - Reuters